5 Key Takeaways From The GPhA Biosimilars Forum

Law360, New York (September 9, 2016, 7:28 PM EDT) -- Top policymakers, attorneys and pharmaceutical executives voiced predictions on upcoming regulation and litigation involving biosimilars at a high-profile conference staged by the Generic Pharmaceutical Association.

The conference on Wednesday and Thursday in North Bethesda, Maryland, featured speeches by top officials from the U.S. Food and Drug Administration and the Federal Trade Commission, leaders of generic-drug makers, and experts from law firms and Wall Street.

Here are five key takeaways from the two-day forum.

FDA Stands Ground on Product Naming

A great deal of discussion centered on...
To view the full article, register now.